Beyond Herceptin and Gleevec

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

1987 • 11,429 citations

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 • 11,070 citations

Gene expression profiling predicts clinical outcome of breast cancer

2002 • 9,314 citations

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

2002 • 2,968 citations

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells

1984 • 2,762 citations

Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome

2001 • 2,749 citations

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

1999 • 2,747 citations

Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences

1984 • 2,564 citations

EGFR and cancer prognosis

2001 • 2,068 citations

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

2003 • 1,939 citations

Humanization of an anti-p185HER2 antibody for human cancer therapy.

1992 • 1,867 citations

Clinical translation of angiogenesis inhibitors

2002 • 1,518 citations

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR

2001 • 981 citations

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

2000 • 848 citations

Specificity within the EGF family/ErbB receptor family signaling network

1998 • 804 citations

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody.

1983 • 792 citations

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.

2001 • 760 citations

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions

1997 • 719 citations

p185^HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor

1989 • 672 citations

The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.

2001 • 670 citations

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity inPten^+/−mice

2001 • 574 citations

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

1989 • 479 citations

Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.

1996 • 423 citations

Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.

1999 • 419 citations

The epidermal growth factor receptor as a target for cancer therapy.

2001 • 339 citations

ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27^Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency

2000 • 304 citations

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

1991 • 296 citations

Involvement of platelet-derived growth factor in disease: development of specific antagonists

2001 • 210 citations

Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.

2002 • 183 citations

Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor.

1992 • 176 citations

Final results from a phase II trial of ZD1839 ("Iressa") for patients with advanced non-small-cell lung cancer (IDEAL 1)

2002 • 175 citations

Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells.

1999 • 172 citations

Influence of Unrecognized Molecular Heterogeneity on Randomized Clinical Trials

2002 • 165 citations

New Insights into the Interaction of Ras with the Plasma Membrane

1999 • 154 citations

Platelet-derived growth factor receptors: A therapeutic target in solid tumors

2001 • 145 citations

The hepatocyte growth factor/ met pathway in development, tumorigenesis, and B-cell differentiation

2000 • 112 citations

Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells.

1991 • 110 citations

Thio- and Oxoflavopiridols, Cyclin-Dependent Kinase 1-Selective Inhibitors: Synthesis and Biological Effects

2000 • 94 citations

Phase II study of SU5416—a small‐molecule, vascular endothelial growth factor tyrosine‐kinase receptor inhibitor—in patients with refractory myeloproliferative diseases

2003 • 81 citations

Receptor Tyrosine Kinases as Therapeutic Targets the Model of the MET Oncogene

2001 • 59 citations

OSI-774 OSI Pharmaceuticals.

2001 • 26 citations

Agents Targeting Ras Signaling Pathway

2002 • 25 citations